In Brief: Genzyme Seprafilm
This article was originally published in The Gray Sheet
Genzyme Seprafilm: Follow-up at 8-12 weeks post-surgery shows that 51% of abdominal surgery patients treated with the bioresorbable membrane do not develop adhesions, according to results of a study presented Oct. 24 at the American College of Surgeons meeting in New Orleans. The success rate compares to a 6% rate for control patients who did not receive the membrane in the 11-center, 183-subject, prospective, randomized, blinded study. Cambridge, Massachusetts-based Genzyme says it plans to submit the data, along with data from a study of gynecologic surgery, in a PMA for Seprafilm...
You may also be interested in...
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.